New Paradigms in the Treatment of Metastatic Hepatocarcinoma: Case Report

Abstract

of The results of the phase III study, IMbrave 150, which compared atezolizumab plus bevacizumab versus sorafenib, represented an important advance in the first-line treatment. We report a clinical case of a 78-year-old patient with metastatic hepatocarcinoma, who underwent first-line treatment with the combination of atezolizumab and bevacizumab. After 3 treatment cycles, there was a complete response in the lung and a partial response in the liver, opening the discussion about the possibility of considering at some point the local treatment of the liver in the face of tumor downstaging.